Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Vertex Pharmaceuticals Incorporated

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases.

We discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases. 

Founded in 1989 in Cambridge, Massachusetts, our corporate headquarters is now located in Boston’s Innovation District, and our international headquarters is in London, United Kingdom. We currently employ approximately 3,500 people in the United States, Europe, Canada, Australia and Latin America with nearly two-thirds of our staff dedicated to research and development.

Vertex is consistently recognized as one of the industry’s top places to work by Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal. Our research and medicines have also received esteemed recognitions, including the Robert J. Beall Therapeutics Development Award, the French Prix Galien and the British Pharmacological Society awards.

Kymera Therapeutics

CRISPR Therapeutics

J.P. Morgan Securities Inc.

Bank of America Merrill Lynch

Morgan Stanley

Goldman Sachs

Janssen Belgium

Norwest Venture Partners

J.H. Whitney & Co

New Enterprise Associates

Greylock

Vertex Pharmaceuticals

Join us in welcoming Lateefah Spires Brown the new San Diego Learning Lab head, to the Vertex team. 

A lifelong educator, Lateefah has a background in biology and a love for all things science — as a child you could even find her scooping up tadpoles and catching fireflies. 

While it was tough for Lateefah to say goodbye to her high school chemistry students, she is excited to work with the next generation of scientists and researchers at our Learning Lab!

For many job candidates, understanding a company’s commitment to inclusion, diversity and equity is a critical part of the decision-making process. Our Vice President of Talent and Inclusion, Diversity and Equity, Diana Cruz Solash, spoke to BioSpace about how candidates can assess a company’s efforts during a job search. 
 
Some takeaways: 
- Check if the job description mentions/reflects the company’s commitment to inclusion, diversity and equity
- Look for signs that the company actively promotes belonging, community building, and professional development for all employees, e.g., through employee resource groups and career development programs
- See if interviewers bring up inclusion, diversity and equity without being prompted — if not, ask about it and listen closely for how those commitments are embedded in the way that people work with each other and in how the company operates
 
Read more perspective from Diana, including on how Vertex reinforces our inclusion, diversity and equity commitment in interviews and in day-to-day working life: https://lnkd.in/ehCbeFXV

Our Vertexians are celebrating the recent news of FDA approval of our gene-edited treatment for #BetaThalassemia. Vertexian Yamila reflects on what this moment means:

“Often, patients are seeing medical providers who are not thalassemia specialists. So the patient is usually responsible for bringing in that knowledge and then advocating for themselves.” — Pranav Saha, a courageous advocate living with #BetaThalassemia 
 
Hear Pranav break down the importance of self-advocacy for people living with beta thalassemia:

#Breaking The U.S. FDA approves our treatment for #BetaThalassemia. We are thrilled to see this approval provide a new option to eligible patients who have been waiting. Learn more: https://lnkd.in/gBBrWdnK

“Our patients always inspire us to never give up.” Paul Negulescu, Senior Vice President, Research, reflects on the last two decades of our drug discovery process and taking on new challenges.

We’re celebrating the extraordinary life, values and legacy of Dr. Martin Luther King, Jr.  

A transformational leader and advocate for nonviolence and equal rights, Dr. King made an indelible impact in the United States and beyond — earning the Nobel Peace Prize in 1964 for his dedication to civil rights. 

#MLKDay is the only U.S. federal holiday designated as a National Day of Service, and the Vertex Foundation is supporting opportunities for Vertexians to give back in the communities in which we live and work.

We care for and care about our people. 

And we’re honored to be named a Best Adoption-Friendly Workplace by the Dave Thomas Foundation. A recognition that we don’t take lightly, we pride ourselves on offering comprehensive benefits that support families. 

Explore our family-building benefits like adoption, surrogacy and more: https://lnkd.in/e4yB6GNb

“’What if?’ is a powerful question,” says Andre Williams, Head of our Boston Learning Lab.
 
“Our STEAM education programs spark this question in our students by engaging them in hands-on scientific experiments as well as exposure to the wide variety of career paths in the biotech industry. Working with students in our local community makes me excited to see the next generation of scientists get their start.” 

#STEAM #SteamEducation  #STEMeducation #SteamEducator #STEM #HandsOn  #21stCenturySkills

The Saudi Food and Drug Authority (SFDA) approves our treatment for #SickleCellDisease and #BetaThalassemia in the Kingdom of Saudi Arabia. Learn more: https://lnkd.in/epWDX4Z6

	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	1.21B -	580.41M 52.11%	1.03B 77.86%	1.70B 64.89%	2.49B 46.20%	3.05B 22.46%	4.16B 36.59%	6.21B 49.07%	7.57B 22.06%	8.93B 17.91%	9.84B 10.17%
cost of revenue	130.28M -	60.99M 53.19%	125.54M 105.85%	210.46M 67.64%	275.12M 30.72%	409.54M 48.86%	547.76M 33.75%	736.30M 34.42%	904.20M 22.80%	1.08B 19.48%	1.26B 16.84%
gross profit	1.08B -	519.43M 51.98%	906.79M 74.58%	1.49B 64.50%	2.21B 48.39%	2.64B 19.18%	3.62B 37.04%	5.47B 51.29%	6.67B 21.96%	7.85B 17.69%	8.58B 9.25%
selling and marketing expenses
general and administrative expenses
selling general and administrative expenses	362.34M -	305.41M 15.71%	377.08M 23.47%	432.83M 14.78%	496.08M 14.61%	557.62M 12.40%	658.50M 18.09%	770.46M 17.00%	840.10M 9.04%	944.70M 12.45%	1.14B 20.31%
research and development expenses	918.78M -	855.51M 6.89%	996.17M 16.44%	1.05B 5.17%	1.32B 26.43%	1.42B 6.93%	1.75B 23.87%	1.83B 4.27%	3.05B 66.77%	2.54B 16.74%	3.69B 45.26%
other expenses	-72.67M -	30.40M 141.83%	-6.71M 122.08%	4.13M 161.52%	-81.38M 2,070.51%	-790K 99.03%	192.18M 24,426.20%	296.42M 54.24%	4.90M 98.35%	-164.80M 3,463.27%	-22.80M 86.17%
cost and expenses	1.41B -	1.22B 13.43%	1.50B 22.66%	1.69B 12.82%	2.10B 23.94%	2.38B 13.73%	2.96B 24.21%	3.34B 12.68%	4.80B 43.73%	4.57B 4.80%	6.09B 33.37%
operating expenses	1.28B -	1.16B 9.38%	1.37B 18.29%	1.48B 7.81%	1.82B 22.98%	1.97B 8.42%	2.41B 22.24%	2.60B 7.75%	3.89B 49.66%	3.48B 10.44%	4.83B 38.50%
interest expense	22.73M -	72.86M 220.56%	84.21M 15.57%	81.43M 3.29%	57.55M 29.33%	34.12M 40.71%	58.50M 71.46%	58.15M 0.60%	61.50M 5.76%	54.80M 10.89%	44.10M 19.53%
ebitda	504.59M -	-611.09M 221.10%	-473.17M 22.57%	15.33M 103.24%	311.45M 1,931.88%	663.18M 112.93%	1.46B 119.83%	3.19B 118.68%	2.79B 12.52%	4.35B 55.81%	3.93B 9.52%
operating income	-903.45M -	-692.41M 23.36%	-468.66M 32.31%	9.94M 102.12%	123.24M 1,140.37%	635.15M 415.36%	1.20B 88.55%	2.86B 138.51%	2.78B 2.60%	4.31B 54.83%	3.75B 12.94%
depreciation and amortization	48.37M -	63.26M 30.79%	62.34M 1.44%	61.40M 1.52%	61.40M 0.00%	72.42M 17.95%	260.31M 259.45%	331.76M 27.45%	6.70M 97.98%	37.80M 464.18%	181.30M 379.63%
total other income expenses net	-776.69M -	-20.52M 97.36%	-8.92M 56.55%	2.87M 132.16%	-350.97M 12,337.38%	-29.61M 91.56%	197.35M 766.60%	260.51M 32.00%	-51.70M 119.85%	-75M 45.07%	629.60M 939.47%
income before tax	-976.12M -	-734.88M 24.71%	-559.58M 23.85%	-67.37M 87.96%	-15.69M 76.71%	600.24M 3,925.87%	1.39B 132.39%	3.12B 123.44%	2.73B 12.40%	4.23B 55.01%	4.38B 3.48%
income tax expense	-288.57M -	6.96M 102.41%	30.38M 336.63%	16.66M 45.15%	-107.32M 744.01%	-1.49B 1,285.40%	218.11M 114.67%	405.15M 85.76%	388.30M 4.16%	910.40M 134.46%	760.20M 16.50%
net income	-445.03M -	-738.55M 65.96%	-558.12M 24.43%	-112.05M 79.92%	263.48M 335.14%	2.10B 695.83%	1.18B 43.88%	2.71B 130.43%	2.34B 13.63%	3.32B 41.84%	3.62B 8.96%
weighted average shs out	224.83M -	234.92M 4.49%	240.84M 2.52%	243.59M 1.14%	248.86M 2.16%	254.29M 2.18%	256.73M 0.96%	259.84M 1.21%	257.70M 0.82%	256.10M 0.62%	257.70M 0.62%
weighted average shs out dil	224.91M -	235.31M 4.62%	241.31M 2.55%	244.69M 1.40%	253.22M 3.49%	259.19M 2.35%	260.67M 0.57%	263.40M 1.04%	259.90M 1.33%	259.10M 0.31%	260.50M 0.54%
eps	-1.98 -	-3.14 58.59%	-2.31 26.43%	-0.46 80.09%	1.06 330.43%	8.25 678.30%	4.58 44.48%	10.44 127.95%	9.09 12.93%	12.97 42.68%	14.05 8.33%
epsdiluted	-1.98 -	-3.14 58.59%	-2.31 26.43%	-0.46 80.09%	1.04 326.09%	8.09 677.88%	4.51 44.25%	10.29 128.16%	9.01 12.44%	12.82 42.29%	13.89 8.35%

NASDAQ:VRTX

Vertex Pharmaceuticals Incorporated

Last Close

400.76

25/04 20:00

Market Cap

110.85B

Beta: 0.49

Volume Today

787.23K

Avg: 1.12M

PE Ratio

31.95

PFCF: 26.33

Please Sign In To Use The Chat